Hospital Administration


Help improve patient outcomes and reduce healthcare costs

As a hospital administrator, you often face difficult and demanding challenges every day. You need to prepare for the demands of an aging population. You must improve patient care by recruiting the most talented staff and you must acquire the most efficient, effective technology.

Plus, you have to navigate the uncertainty of healthcare reform, including Medicare and Medicaid reimbursements and the transition from fee-for-service to alternative payment models (APMs). All while streamlining costs and maintaining fiscal responsibility. At CSI, we are committed to offering technology that helps improve patient outcomes and delivers value.

Learn More About Our Portfolio of Products

Patient Stories

Helping you get your patients back to what matters

Treat Peripheral Artery Disease

Orbital atherectomy can be a critical element in a revascularization-first strategy. Amputation is among the costliest treatment options.36,37 The cost for an advanced PAD patient, one with critical limb ischemia (CLI), following a lower extremity amputation is $49,000 annually.12

Revascularization procedures result in demonstrated improvements in patient outcomes and reduced costs when compared to amputation.13,14,37 It’s estimated that a 25% reduction of amputations could save $2.9 billion to $3 billion in healthcare expenditures in the US54

$212 billion


$389 billion

annual PAD direct costs*55

*Includes inpatient and outpatient costs, including all-cause hospitalizations, medications and other costs for PAD patients in the US REACH population in 2015 ($10,881 x 19.5 million people with PAD) and managed care population in 2014 ($19,963 x 19.5 million people with PAD). Range calculated by The SAGE Group, 2015.

>1 million

physician office visits with a primary diagnosis of PAD in 201238

19 thousand

emergency department visits for PAD in 201138

291 thousand

outpatient department visits for PAD in 201138

Treat Severely Calcified Coronary Lesions

The annual burden of illness due to coronary artery calcification is estimated at between $1 billion and $3 billion.18 The burden for all heart diseases will escalate in the future, according to the American Heart Association (AHA). The AHA estimates that by 2030, 40.5% of the US population will have some form of cardiovascular disease, costing an estimated US $818 billion.4

Patients with severe calcification present a greater risk of complication rates, which increases overall hospitalization costs.4,19 Orbital atherectomy can be a critical tool for severely calcified lesions to enable successful stent deployment with low complication rates.10,5960

Hospital Administration Bubble Graphic
Example only based on United States national estimates. Actual reimbursement rates may vary. Estimated Medicare national average overhead. ORBIT II cost-effectiveness study7 with Extrapolation of 1-year economic data to 2-year estimates by Brad J. Martinsen, Ph.D. (CSI). Regression analysis with a Power line fit to give predicted 730-day cost offset/savings. Podium Presentation at EuroPCR 2015, Paris and Data on file at CSI. Medicare comparison sample was drawn from the 100% Standard Analytical File for reported period. The base case analysis was restricted to calcification patients from hospitals (N=17) reporting more the 10% of stent patients with calcification during this initial period. PCI patients with severely calcified lesions with acute coronary syndrome. Study design and enrollment criteria differ from ORBIT II.

Commitment to Clinical & Economic Rigor

Physicians and payers are increasingly seeking clinical and economic evidence to allow them to make decisions regarding optimal treatment of patients. We are focused on conducting and collecting clinical and economic evidence to demonstrate the advantages of OAS in treating complex disease states such as PAD and CAD.

We believe that the clinical data and cost-effectiveness of our OAS technology will help drive physician utilization of the OAS and sustain ongoing reimbursement coverage for our devices.4,7,18,58

Clinical Evidence

We believe true innovation is a product of tireless investigation

*Includes PAD and CAD clinical evidence









For more information on CSI products and technologies

The owner of this website has made a commitment to accessibility and inclusion, please report any problems that you encounter using the contact form on this website. This site uses the WP ADA Compliance Check plugin to enhance accessibility.